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Background: The National Comprehensive Cancer Network (NCCN) recommends conservative follow-up for gastric
gastrointestinal stromal tumors (GISTs) less than 2 cm. The aim of the present study was to investigate the clinical
and pathological features of small gastric GISTs, re-evaluate the risk potential, and discuss the treatment strategy of
small gastric GISTs.
Methods: In this retrospective study, 63 cases of small gastric GISTs (less than 2 cm) were resected surgically from
May 2010 to March 2013 in our department. Clinicopathological factors were collected and the malignant potential
of small gastric GISTs was analyzed.
Results: The mitotic index of 14 out of 63 cases (22.22%) exceeded 5. The malignant potential of small gastric GISTs
was related to tumor location (P = 0.0218). The mitotic index of 4 out of 8 GISTs (50%) located in gastric cardia
exceeded 5, 8 out 28 GISTs (28.57%) located in the gastric fundus exceeded 5, and only 2 out of 27 GISTs (7.41%)
located in the gastric body exceeded 5. We also discovered a good consistency between mitotic index and Ki-67
expression of small gastric GISTs.
Conclusions: Gastric GISTs less than 2 cm also have malignant potential. Thus, we recommended surgical resection
of all small gastric GISTs once diagnosed.
Keywords: Gastric gastrointestinal stromal tumor, Malignant potential, Mitotic index, Gene mutationBackground
Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumor of the gastrointestinal
tract and represent 1% to 2% of all gastrointestinal ma-
lignancies [1]. They are considered to be derived from
the interstitial cells of Cajal, the pacemaker cells of the
gastrointestinal tract [2]. This has been established by
immunohistochemical staining of GISTs for CD117,
CD34, smooth muscle actin, desmin and S-100 [3]. In
1998, Hirota et al. reported that GISTs are associated
with gain-of-function mutations in the KIT proto-
oncogene [2]. Histologically, most GISTs display spindle* Correspondence: zhanghwfmmu@126.com
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reproduction in any medium, provided the orcell morphology (70%), whereas a minority is of epitheli-
oid (20%) or mixed phenotypes (10%) [4]. GISTs can
occur anywhere throughout the gastrointestinal tract
and are seen most commonly in the stomach (40 to
70%), small intestine (20 to 40%), and colon and rectum
(5 to 15%) [5]. Rare cases have been reported in the
esophagus, appendix, greater omentum, and gallbladder
[6]. Patients with gastric GISTs may be completely
asymptomatic or present with abdominal pain, dyspep-
sia, anorexia, bleeding, obstruction or tarry stool [7].
According to the NCCN guideline [8], gastric GISTs
less than 2 cm and with a mitotic index (number of mi-
toses per 50 HPF (high-power fields)) less than 5 were
considered as very low risk. Thus, surgical intervention
with negative margins is the treatment of choice for pri-
mary, localized gastric GISTs larger than 2 cm, while
conservative follow-up is suggested for lesions less thand. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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malignant potential [12], including small gastric GISTs
(less than 2 cm). To date, little is known about the nat-
ural course of small gastric GISTs, and no literature has
reported the mitotic index and gene mutation spectrum
of small gastric GISTs.
Given this situation, we presume that the treatment
principle of gastric GISTs less than 2 cm should be
reconsidered. In the present study, we retrospectively
analyzed the clinical and pathological data of 63 patients
with gastric GISTs less than 2 cm. The aim of the
present study was to reevaluate the risk potential and re-
consider the treatment principle of small gastric GISTs.
Methods
Patients
This study was performed in the Xijing Hospital of Di-
gestive Diseases affiliated to the Fourth Military Medical
University. From May 2010 to March 2013, a total of 63
patients who were suspected of having a small gastric
GIST (maximum diameter ≤2 cm) as a result of examin-
ation by endoscopic ultrasound (EUS) and enhanced ab-
dominal computed tomography (CT) were enrolled in
the present study. Surgical resection was performed by
surgeons who are specialized in gastric surgery in our
department. This study was approved by the Ethics
Committee of Xijing Hospital, and written informed
consent was obtained from all patients before surgery.
Pathology
All the specimens were fixed in 10% neutral formalin im-
mediately after resection and embedded routinely for histo-
logic examination in the Pathology Department in the
Xijing Hospital. Immunohistochemistry was performed on
3-μm sections according to the manufacturer's instructions
and the following antibodies: CD117 (polyclonal, 1:200;
DAKO, Hamburg, Germany), CD34 (clone QBEnd10,
1:200; Immunotech, Hamburg, Germany), Discovered on
GIST-1 (monoclonal DOG-1, 1:200; Novocastra, Newcastle,
UK), Ki67 (clone MIB1, 1:150, DAKO). Histological type
(spindle, epithelioid, mixed) and mitotic index were also
detected by hematoxylin and eosin stain.
Gene mutation detection
DNA of the GIST tissues was isolated using a QIAmp
DNA FFPE Tissue kit according to manufacturer’s in-
structions (Qiagen, Hilden, Germany). Polymerase chain
reaction (PCR) was used to amplify KIT exons 9, 11, 13
and 17 and PDGFRA exons 12 and 18. The PCR reaction
was performed using a Taq PCR Master Mix according to
manufacturer’s instructions (Qiagen, Hilden, Germany).
Mutations were confirmed by comparing the sequencing
results with gene sequences in the NCBI Genbank. Pri-
mers used in PCR were listed as follows: KIT exon 9forward: TCCTAGAGTAGTAAGCCAGGGCTT, KIT exon
9 reverse: TGGTAGACAGAGCCTAAACATCC, KIT exon
11 forward: CCAGAGTGCTCTATAGACTG, KIT exon 11
reverse: AGCCCCTGTTTCATACTGAC, KIT exon 13 for-
ward: GACATCAGTTTGTCAGTTG, KIT exon 13 reverse:
GCAAGAGAGAACAACAG, KIT exon 17 forward: GTGA
ACATCATTCAAGGCG, KIT exon 17 reverse: TTACATT
ATGAAAGTCACAGG, PDGFRA exon 12 forward: TCCA
GTCACTGTCCTGCTTC, PDGFRA exon 12 reverse: GCA
AGGGAAAAGGGAGTCTT, PDGFRA exon 18 forward:
ACCATGGATCAGCCAGTCTT, PDGFRA exon 18 reverse:
TGAAGGAGGATGAGCCTGACC.
Statistical analysis
Data were processed using SPSS 16.0 for Windows
(SPSS Inc., Chicago, IL, USA). Numerical variables were
expressed as the mean ± SD unless otherwise stated.
Discrete variables were analyzed using the Chi-square
test or Fisher's exact test. The consistency of the mitotic
index and the Ki-67 was analyzed using McNemar’s test
and the Kappa test. The P values were considered to be
statistically significant at the 5% level.
Results
Patient and tumor characteristics
Clinical and pathological characteristics of the patients
and tumors are summarized in Table 1. Sixty-three
patients meeting the criteria for the diagnosis of EUS-
suspected small gastric GISTs were enrolled, and com-
prised 39 men and 24 women. The average age was
62.44 ± 9.76 years (range: from 39 to 89 years). Approxi-
mately 73.02% of the patients were symptomatic. Pre-
senting symptoms included abdominal pain (28.57%),
bleeding (7.94%), and abdominal discomfort (36.51%).
On the basis of the EUS, pathology and operative report,
8 tumors were located in the cardia, 28 tumors in the
gastric fundus, and 27 tumors in the gastric body. Ap-
proximately 22.22% of the patients had more than 5 mi-
totic figures per 50 HPF, and 22.22% of the patients had
a positive Ki-67 stain (>5%). A total of 61 of the 63 cases
studied (96.83%) stained positive for CD117, 61 of the
63 cases (96.83%) stained positive for DOG-1, and 62 of
the 63 cases (98.41%) stained positive for CD34. Molecu-
lar analysis revealed KIT exon 11 mutation in 47 cases,
KIT exon 9 mutation in 3 cases, KIT exon 13 mutation
in one case, KIT exon 17 mutation in one case, PDGFRA
exon 18 mutation in one case, and wild type in 10 cases.
The relationship between mitotic activity and clinical features
The correlations of mitotic activity and clinical features
are summarized in Table 2. The results show that the
mitotic index was not statistically different and had no cor-
relations with age, sex, tumor size and clinical symptoms.
However, the mitotic index was related to the location of
Table 1 Clinical and pathological features of small gastric
gastrointestinal stromal tumors (GISTs)
Characteristics Cases (n = 63)





























KIT exon 11 47
KIT exon 9 3
KIT exon 13 1
KIT exon 17 1
PDGFRA exon 12 0
PDGFRA exon 18 1
Wild type 10
Table 2 The relationship between mitotic activity and
clinical features
Characteristics Mitotic index Statistics
Age ≤5 >5
≤50 7 1 P = 0.1400
51to 60 8 4
61to 70 27 4
>70 7 5
Sex
Male 31 8 P = 0.7591
Female 18 6
Tumor size
≤1 cm 29 4 P = 0.0678
1 to 2 cm 20 10
Tumor location
Cardia 4 4 P = 0.0218
Gastric fundus 20 8
Gastric body 25 2
Clinical symptoms
Symptomatic 34 12 P = 0.3155
Asymptomatic 15 2
Table 3 The consistency of mitotic index and Ki-67




Mitotic index ≤5 46 3 P = 1.0000
>5 3 11 Kappa = 0.724
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50 HPF) was highest in the GISTs located in the cardia
(50%) and lowest in the gastric body (8%). No GIST was
found in the gastric antrum in our present study. Although
the ratio of mitotic index (>5 per 50 HPF) of gastric GISTs
between 1 to 2 cm was higher than that of gastric GISTs
less than 1 cm (33.33% versus 12.12%), there was no signifi-
cant difference between the two groups.McNemar’s test and the Kappa test were used to
measure the agreement between mitotic index and ex-
pression of Ki-67 of small gastric GISTs. The results in
Table 3 show a good consistency between mitotic index
and Ki-67 expression (P = 1.0000, Kappa = 0.724).
Discussion
The management of GISTs is generally based on tumor size
because biopsy is not recommended and mitotic index can-
not be easily and accurately determined [13]. The National
Comprehensive Cancer Network recommends surgical re-
section for tumors greater than 2 cm because of malignant
potential, and lesions less than 2 cm can be conservatively
followed up [14]. As a result, the malignant potential of
small gastric GISTs could not be accurately determined
due to the lack of mitotic index based on pathology. How-
ever, every GIST is now regarded as potentially malignant,
and even GISTs with low mitotic rates were reported to
recur locally or to metastasize [15]. The present study
sought to identify the clinical and pathological features of
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small gastric GSITs.
As a specific marker of GISTs, CD117 has good sensi-
tivity and was highly expressed in nearly 85% to 94% of
cases [16]. The high sensitivity and specificity of CD117
is a useful marker in differentiating GIST from other
mesenchymal tumors of the gastrointestinal tract. DOG1
(Discovered on GIST-1) is a newly identified marker of
GISTs, West et al. reported ubiquitous expression of
DOG-1 in GISTs and demonstrated the immunoreactiv-
ity for DOG-1 in 97.8% of GISTs [17]. Many reports
showed that the sensitivity for CD117 and DOG1 are al-
most the same, and the two factors have consistency. As
a hematopoietic progenitor cell antigen, CD34 is com-
monly present in GISTs but is less specific than CD117
and DOG1. The positive rate of CD34 is approximately
60% to 70% [18]. In our present study, the clinical and
pathological characteristics of small gastric GISTs were
in agreement with the references reported. These indi-
cate that there is no significant difference in the clinical
and pathological features between the small gastric
GISTs in our study and the GISTs reported previously.
Tumor size and mitotic index are the best prognostic
indicators for determining the malignant potential of
GISTs [19]. In our present study, although all the gastric
GISTs were less than 2 cm, the mitotic index of 14 small
gastric GISTs was greater than 5 per 50 HPF. It was
striking to observe that 22.22% of small gastric GISTs
showed low risk, which indicated the malignant poten-
tial and implied the necessity of surgical resection of
small gastric GISTs. Furthermore, we analyzed the rela-
tionship between tumor size (≤1 cm versus 1 to 2 cm)
and mitotic index. We found that there was no signifi-
cant difference between the two groups, and the mitotic
index of 4 out of 33 gastric GISTs (≤1 cm) was greater
than 5 per 50 HPF. In this situation, we think that all
GISTs should be resected once diagnosed. Besides tumor
size and mitotic index, the location of GIST is also con-
sidered as one of the risk factors. It is reported that the
location of GISTs in the gastric cardia and gastroesopha-
geal junction is an unfavorable prognostic factor [20]. In
our present study, 8 gastric GISTs were located in the
gastric cardia, and the mitotic index of 4 cases exceeded
5, demonstrating that GISTs located in the gastric cardia
possess more malignant potential than those located in
the gastric fundus and gastric body.
The current management policy for gastric GISTs less
than 2 cm is usually conservative, unless tumors grow or
symptoms occur [21]. In our present study, 46 of 63 cases
(73.02%) were presented with symptoms including pain,
bleeding and discomfort. The high rate of presenting symp-
toms resulted from the combination of gastric cancer and
gastric GIST of patients in our study. Even in the remaining
17 asymptomatic patients, the mitotic index of 2 cases wasmore than 5 per 50 HPF, indicating malignant potential.
These findings also indicate that gastric GISTs less than 2
cm should be resected once diagnosed because most of the
small gastric GISTs presented with symptoms, and some
asymptomatic cases possessed malignant potential.
In 1998, Hirota et al. reported their groundbreaking dis-
covery of KIT mutations in GISTs. It is now established
that 70% to 80% of GISTs harbor a KIT gene mutation
[22]. Most of these are exon 11 mutations, which cause
constitutively activated receptors leading to unregulated
autophosphorylation of the intracytoplasmic tyrosine ki-
nases [23]. KIT mutations in exons 9, 13 and 17 are less
common and have been associated with more aggressive
tumor behavior [20]. PDGFRA mutations occur in ap-
proximately 20% to 25% of gastric GISTs, and most com-
monly in exon 18 [24]. KIT and PDGFRA mutations are
mutually exclusive [25]. Very rare cases may have muta-
tions in the BRAF kinase [26]. GISTs without a mutation in
either KIT or PDGFRA genes account for about 10% to 15%
of GISTs and are known as wild type [27]. In our present
study, 74.60% of small gastric GISTs harbor a KIT exon 11
mutation, 4 cases (4.76%) harbor a KIT exon 9 mutation,
one case (1.59%) harbors a KIT exon 13 mutation and one
case (1.59%) harbors a KIT exon 17 mutation. One case
(1.59%) harbors a PDGFRA exon 18 mutation, and 10 cases
(15.87%) were wild type. These results demonstrate that the
gene mutation spectrum of small gastric GISTs in our
present study is in agreement with the references reported.
Some authors have proposed the use of Ki-67 as a
more objective parameter for risk assessment, because
multivariate analyses in several studies do indicate that
Ki-67 index could be independently used as an outcome
predictor [28]. In our present study, the consistency of
the mitotic index and Ki-67 expression was analyzed
using McNemar’s test and the Kappa test. The results
showed a good consistency between mitotic index and
Ki-67 expression. This indicated that Ki-67 expression
may also be considered as a prognostic indicator for de-
termining the malignant potential of gastric GISTs.
There are several limitations in the present study.
First, no recurrence-free survival rate of patients who re-
ceived surgical resection of small gastric GISTs could be
obtained. Second, further studies should be carried out
to investigate the necessity of medication after surgical
resection. Third, multicenter randomized controlled
studies should be carried out to confirm the benefit of
surgical resection of small gastric GISTs compared with
conservative patients.
Conclusions
Through pathological examination and gene mutation
analysis, we found that some gastric GISTs less than 2 cm
also harbor malignant potential, and recommend surgical
resection of all small gastric GISTs once diagnosed. Thus,
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should be reconsidered.
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